Human Tissue factor pathway inhibitor,TFPI ELISA Kit

Code CSB-E08260h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
Alternative Names
Anti convertin ELISA Kit; EPI ELISA Kit; Extrinsic pathway inhibitor ELISA Kit; LACI ELISA Kit; Lipoprotein associated coagulation inhibitor ELISA Kit; Lipoprotein-associated coagulation inhibitor ELISA Kit; TFI ELISA Kit; TFPI 1 ELISA Kit; TFPI ELISA Kit; TFPI1 ELISA Kit; TFPI1_HUMAN ELISA Kit; Tissue factor pathway inhibitor (lipoprotein associated coagulation inhibitor) ELISA Kit; Tissue factor pathway inhibitor ELISA Kit
Abbreviation
TFPI
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.782 ng/mL-50 ng/mL
Sensitivity
0.293 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cardiovascular
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human TFPI in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %93
Range %88-97
1:2Average %101
Range %97-105
1:4Average %94
Range %89-98
1:8Average %96
Range %91-102
Recovery
The recovery of human TFPI spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9489-98
EDTA plasma (n=4)8681-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
502.519 2.623 2.571 2.440
252.021 2.154 2.088 1.957
12.51.434 1.456 1.445 1.314
6.250.813 0.838 0.826 0.695
3.1250.436 0.445 0.441 0.310
1.5630.304 0.310 0.307 0.176
0.7820.221 0.216 0.219 0.088
00.130 0.131 0.131
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This human TFPI ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human TFPI in serum, plasma, or tissue homogenates. It also uses the enzyme-substrate chromogenic reaction to visualize and analyze the analyte levels through the color intensity. The intensity of the colored product is in direct proportion to the TFPI levels in the sample and is measured at 450 nm through a microplate reader.

TFPI is an anticoagulant protein produced primarily by the endothelium and megakaryocytes. It is the main inhibitor of the TF-dependent pathway of blood coagulation. TFPI mediates its anticoagulant activity by impeding early proteolytic events of the blood coagulation cascade, including those mediated by the TF-FVIIa catalytic complex, FXa, and early forms of the prothrombinase complex (FVa-FXa). TFPI can also enhance the effect of heparins. Studies have shown that TFPI exerts anti-angiogenic and anti-metastatic effects in vitro and in vivo. TFPI plays a significant role in the pathophysiology of many diseases, including cancer and inflammation.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Gene References into Functions
  1. plasma level not different between pre-eclampsia and normal pregnancy PMID: 28521572
  2. Patients with early onset preeclampsia are characterised by an attenuated coagulation response characterised by reduced thrombin generation stimulated by low-dose TF and elevated plasma TFPI activity. PMID: 28569919
  3. Developed functional protein S assays that measure both the activated protein C- and TFPI-cofactor activities of protein S in plasma, which are hardly if at all affected by the FV Leiden mutation. PMID: 28211163
  4. These data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI. PMID: 28482260
  5. Among the various candidate genes involved in acute rejection, CD47 inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 signal regulatory protein alpha (SIRP-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47, thrombospondin-1 (TSP-1). PMID: 28393401
  6. Tissue Factor Pathway Inhibitor Gene Polymorphism is associated with response to therapy in Colorectal Cancer. PMID: 26968713
  7. For the first time, we show that a TFPI variant is significantly associated with fibrinogen levels and risk of coronary artery disease. PMID: 28894953
  8. miR-27a/b and miR-494 regulate TFPIalpha expression; there may be a role of these miRNAs in the estrogen-mediated downregulation of TFPIalpha PMID: 26999003
  9. Genetic variations of the TFPI genes seem to be related with coronary artery disease, which likely cooperate with metabolic risk factor (diabetes mellitus) and play critical roles in the pathogenesis of coronary artery disease in Han Chinese. PMID: 28716011
  10. Cleavage of FV at Arg(1545) , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIalpha C-terminus to the FV acidic region PMID: 27801970
  11. The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis. PMID: 28749986
  12. The results show that cholesterol crystals induce TFPI and cytokine expression in M2-polarized macrophages through activation of the endoplasmic reticulum stress pathway and that TFPI has a protective effect against TNF-alpha and IL-6 mediated inflammation. PMID: 28712870
  13. Among high-risk women, the tissue factor pathway inhibitor activity of patients with gestational vascular complications is higher than that in other patients. Hence, these markers could augment a screening strategy. PMID: 28328938
  14. TFPI single nucleotide polymorphism is associated with venous thromboembolism. PMID: 28421636
  15. a concentration of tissue factor pathway inhibitor was significantly lower in patients with essential thrombocythemia with JAK2 V617F mutation as compared with patients without the mutation PMID: 26945263
  16. This review presents a comprehensive understanding of TFPI structure, biochemistry, and cellular expression which is necessary to understand how it modulates bleeding in hemophilia and the physiological impact of therapeutic agents targeting TFPI. PMID: 27207418
  17. the main finding of the current study is the remarkable elevation in the plasma levels of both total and free TFPI in septic patients at baseline. The levels of both forms of the inhibitor remained elevated throughout the first 24 h with further elevation after enoxaparin administration. PMID: 26377606
  18. TFPI-1 was a valuable predictor of deep venous thrombosis and tumor metastasis in non-small cell lung cancer patients. PMID: 28246607
  19. Circulating FVII, FVIIa and TFPI were significantly elevated in women with severe preeclampsia in the absence of comparable changes in plasma TF levels. PMID: 26765308
  20. HIF-1alpha is involved in the transcriptional regulation of the TFPI gene, and suggests that a hypoxic microenvironment inside a breast tumor may induce a procoagulant state in breast cancer patients. PMID: 26598923
  21. ERalpha can interact with all three ERE half-sites in the TFPI 5'-flanking region. PMID: 26999742
  22. rs5940 and rs7586970 moderate TFPI plasma levels and are candidate risk factors for thrombosis, but the regulation of TFPI plasma levels involves genetic factors beyond the TFPI gene. Review. PMID: 25879386
  23. Tissue factor pathway inhibitor activity and APC resistance are related to coronary heart disease risk in women, but may not explain the increased CHD risk due to estrogen plus progestin therapy. PMID: 26681757
  24. Association between genetic polymorphisms and deep vein thrombosis in a Chinese population. PMID: 26233570
  25. coagulation system, TFPI play an important role in the pathogenesis of CRSwNP. PMID: 26163243
  26. A significant degradation of TFPI was induced by ROS exposure, resulting in a decreased ability to bind FXa. ROS induce a procoagulant state in endothelial cells by altering TFPI structure, resulting in inhibition of TFPI binding to Factor Xa PMID: 25712553
  27. TNFalpha and Stx-1 compared to TNFalpha alone leads to an increase in procoagulant TF on endothelial cells, which is explained by a significant decrease in TFPI not co-localized with TF and not to an increase in TF not co-localized with TFPI PMID: 25864889
  28. Direct inhibition of FXa by TFPIalpha inhibits thrombin generation and contributes to the downregulation of coagulation. PMID: 25348176
  29. Tissue factor pathway inhibitor-2 gene polymorphisms were associated with coronary atherosclerosis in the Chinese population PMID: 26496276
  30. This study indicates that genetic and phenotypic variation of both TFPIalpha and TFPIbeta, more than TF, are markers of cancer progression. PMID: 25882602
  31. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells PMID: 25617766
  32. Describe inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs. PMID: 25163770
  33. Neither genetic polymorphisms nor the plasma levels of TFPI seem to act as direct risk factors for venous thromboembolism. PMID: 24448154
  34. Thrombin decreases TFPI expression in human pleural mesothelial cells. PMID: 25303460
  35. Colon TFPI levels are increased in ulcerative colitis. PMID: 24966616
  36. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. PMID: 25359215
  37. Most capillary endothelial cells of the cholecystitis group presented weak expression for TFPI. PMID: 24716194
  38. TFPI is an early biomarker in myocardial infarct and may explain the final infarct size. PMID: 24461489
  39. genetic polymorphism affects endogenous thrombin potential among FV Leiden carriers PMID: 24226152
  40. Data indicate that the protein S sex hormone-binding globulin (SHBG)-like domain was important for binding and enhancement of tissue factor pathway inhibitor (TFPI). PMID: 24740810
  41. Studies indicate differential expression of tissue factor pathway inhibitor isoforms TFPIalpha and TFPIbeta in platelets and endothelial cells. PMID: 24620349
  42. TFPI mRNA expression was increased in clear cell carcinoma (P<0.01). PMID: 24094893
  43. Both the protein S and the TFPI ratios were increased in patients with cirrhosis compared to controls. PMID: 23841464
  44. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). PMID: 24275667
  45. Demonstrate a 5' untranslated region alternative splicing event that alters translation of TFPI isoforms produced via independent 3' splicing events within the same gene. PMID: 24233486
  46. PS exerts anticoagulant cofactor activity with TFPIalpha from any physiological pool, likely by localizing TFPIalpha to membrane surfaces, stabilizing its interaction with membrane-bound FXa, and slowing thrombin generation. PMID: 24233490
  47. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. PMID: 24127605
  48. The east Texas bleeding disorder-associated F5(A2440G) mutations leads to the formation of the TFPIalpha:FV-short complex, which inhibits activation and propagation of coagulation. PMID: 23979162
  49. The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk of venous thrombosis associated with oral contraceptives. PMID: 23407778
  50. tissue factor pathway inhibitor has a role in coagulation in hemostasis, particularly when FVIII is missing PMID: 23348798

Show More

Hide All

Subcellular Location
[Isoform Alpha]: Secreted.; [Isoform Beta]: Microsome membrane; Lipid-anchor, GPI-anchor.
Tissue Specificity
Mostly in endothelial cells.
Database Links

HGNC: 11760

OMIM: 152310

KEGG: hsa:7035

STRING: 9606.ENSP00000233156

UniGene: Hs.516578

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1